Live webinar · Register

When everyone can find your bugs: medical device security after AI.

AI has collapsed the cost of vulnerability discovery to nearly zero. Manufacturers now face more findings per product, per release, than any team can triage by hand, each one needing an evidenced disposition under FDA premarket (524B) and postmarket expectations.

FDA 524B & postmarketBuild your own AI verificationCI/CD feedback loop
Reserve your seat
About this webinar

From point-in-time testing to continuous AI-driven verification.

This webinar examines the trend and the AI-based response: developing your own AI automated analysis to determine which vulnerabilities are actually exploitable against a specific device rather than theoretically present in it.

The migration path

We walk through a practical route from manual, point-in-time testing to continuous AI-driven discovery and verification, including how to build a feedback loop that routes verified findings directly into your CI/CD pipeline in a quality-system-compliant manner.

What you'll leave with

A transition strategy: where to start, what to automate first, and how to keep pace with discovery that no longer has a barrier to entry.

What you'll learn

Six takeaways for product security and regulatory leaders.

Why discovery went exponential

AI tools tear through products at a speed humans can't match. Everyone can find your bugs now, including researchers, regulators, and attackers.

Finding vs. understanding

The bottleneck moved. The challenge is no longer finding vulnerabilities. It is knowing which ones are actually exploitable against your product.

Build your own AI analysis

How to develop automated analysis that determines real exploitability against a specific device, not theoretical presence in it.

A CI/CD feedback loop

How to route verified findings directly into your pipeline in a quality-system-compliant manner, so proof lands where the code is built.

An evidenced disposition

Why every finding needs a defensible call under FDA 524B and postmarket expectations, and how to produce it at volume.

A transition strategy

Where to start, what to automate first, and how to keep pace with discovery that no longer has a barrier to entry.

"AI has collapsed the cost of vulnerability discovery to nearly zero. The manufacturers who prepare now will spend next year shipping. The ones who don't will spend it explaining themselves to regulators."

Jason Sinchak · CEO & Co-founder, ELTON Cyber

Your speaker

Jason Sinchak, CEO and co-founder of ELTON Cyber, has spent more than a decade testing medical devices and has taken 600+ vulnerability reports through FDA review.

Get started

See your device through ELTON.

Start with one device. We build the twin from documentation your quality system already produces, run AI discovery remotely, and show you the graph: the handful to fix, and the evidence for everything else.

Automate medical device vulnerability discovery and verification. FDA §524B methodologyExploitability proven on-device95% faster than legacy testing Book a Demo
Platform
Platform OverviewDigital TwinAutonomous TestingExploitability VerificationVulnerability GraphRemediation OptimizationELTON TestLink™Lifecycle & MetricsCVSSv4 Migration
Solutions
FDA §524BEU MDR/CRAEU REDNIS2IMDRF N60 / N73Postmarket SurveillanceIncident Response
Why ELTON
Why ELTONPricing
Resources
Intelligence & BlogRegulatory GuidesWebinarsWhitepapers
Company
AboutLeadershipCareersContact Book a Demo